

## MARKSANS PHARMA LIMITED

Regd. Office: 21st Floor, Lotus Business Park, Off. New Link Road, Andheri [West], Mumbai-400053

### UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED ENDED 30TH SEPTEMBER 2009

Rs.in Lacs

Sr. No.	PARTICULARS	For the Quarter ended on		For the Period ended on		For the year ended on
		30.9.2009 (UNAUDITED)	30.9.2008 (UNAUDITED)	30.9.2009 (UNAUDITED)	30.9.2008 (UNAUDITED)	31st March 09 (AUDITED)
1	Income					
	a>. Net Sales/ Income from Operations	7,704.05	11,521.71	17,360.89	18,737.36	36,013.10
	b>. Other Operating Income	23.98	261.15	86.72	268.66	806.40
	<b>Total Income</b>	<b>7,728.03</b>	<b>11,782.86</b>	<b>17,447.61</b>	<b>19,006.02</b>	<b>36,819.50</b>
2	Expenditure					
	a>. Increase/Decrease in stock in trade	428.33	225.11	(179.97)	(88.37)	(859.69)
	b>. Consumption of Material & Purchases	5,121.66	7,321.30	12,881.90	11,463.46	25,151.46
	c>. Employee Cost	916.65	938.85	1,826.73	1,707.58	3,737.21
	d>. Depreciation	380.14	300.89	767.38	569.69	1,535.45
	e>. Other Expenditure	932.88	1,476.51	2,202.50	2,395.79	5,819.05
	<b>Total Expenditure</b>	<b>7,779.66</b>	<b>10,262.66</b>	<b>17,498.54</b>	<b>16,048.15</b>	<b>35,383.48</b>
3	Profit from Operations before other income					
	Interest & Exceptional Items (1-2)	(51.63)	1,520.20	(50.93)	2,957.87	1,436.02
4	Other Income			-	-	-
5	Profit before Interest & Exceptional item (3+4)	(51.63)	1,520.20	(50.93)	2,957.87	1,436.02
6	Interest	608.76	657.44	1,147.53	1,005.54	2,135.94
7	Profit after Interest but before Tax Exceptional items	(660.39)	862.76	(1,198.46)	1,952.33	(699.92)
8	Exceptional items- Earlier year taxation	(44.52)	21.39	-	21.39	-
9	<b>Profit/(Loss) from Ordinary activities before Tax (7+8)</b>	<b>(704.91)</b>	<b>841.37</b>	<b>(1,198.46)</b>	<b>1,930.94</b>	<b>(699.92)</b>
10	Tax Expenses - Subsidiary company	30.16	101.90	33.54	188.96	95.57
11	<b>Net Profit/(loss) from Ordinary activities after tax(9-10)</b>	<b>(735.07)</b>	<b>739.47</b>	<b>(1,232.00)</b>	<b>1,741.98</b>	<b>(795.49)</b>
12	Extraordinary Item- Minority Interest	11.41	32.67	29.74	82.05	40.05
13	<b>Net Profit/ (Loss) for the period (11-12)</b>	<b>(746.47)</b>	<b>706.80</b>	<b>(1,261.74)</b>	<b>1,659.93</b>	<b>(835.54)</b>
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,678.05	3,678.05	3,678.05	3,678.05	3,678.05
15	Reserve Excluding Revaluation Reserve as per					
	Balance sheet of Previous Accounting year	-	-	-	-	10,000.66
16	a>. Earnings Per Share (Basic & Diluted)	(0.20)	0.20	(0.33)	0.47	(0.22)
	(before extraordinary items.Rs.)					
	b>. Earnings Per Share( Basic & Diluted)	(0.20)	0.19	(0.34)	0.45	(0.23)
	(after Extraordinary items- Rs.)					
17	Aggregate of Public Shareholding:					
	- Number of Shares	189,822,361	189,772,361	189,822,361	189,772,361	188,222,361
	- Percentage of Holding	51.61%	51.59%	51.61%	51.59%	51.17%
18	Promoters and Promoter group Shareholdings	177,983,510	178,033,510	177,983,510	178,033,510	179,583,510
	a>. Pledged/Encumbered					
	- Number of Shares	NIL	-	NIL	-	NIL
	- Percentage of Holding	N.A	-	N.A	-	N.A

	(as a % of the total shareholding of Promoter and Promoter Group)					
	- Percentage of Holding	N.A	-	N.A	-	N.A
	(as a % of the total share capital of the Company)					
a>	Non-encumbered					
	- Number of Shares	177,983,510	178,033,510	177,983,510	178,033,510	179,583,510
	- Percentage of Holding	100%	100%	100%	100%	100%
	(as a % of the total shareholding of Promoter and Promoter Group)					
	- Percentage of Holding	48.39%	48.41%	48.39%	48.41%	48.83%
	(as a % of the total share capital of the Company)					

**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30.10.2009.
- 2 Board of Directors have taken following decision, subject to other approvals whenever necessary and the prevailing market condition.
  - i> To restructure business model of the company/ Hiving off API division of the company and to focus more on the Global Formulation Division.
  - ii>.To raise capital through issue of equity or equity linked instruments upto Rs.200 crores.
- 3 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 4 The Consolidated Financial Statements Include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- 5 Marksans Pharma (U.K.) Ltd, a subsidiary of Marksans Pharma Ltd, acquired Bell, Sons & co (Druggists) Limited on 18.01.2008 and Relonchem Limited on 27.08.2008. Therefore to that extent the corresponding results of previous year are not comparable.
- 6 The Consolidated Financial Statement are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountant of India.
- 7 No Provision have been made during the year for Foreign Exchange Difference account in case of Foreign Currency Convertible Bond. The Management is of the opinion that the determination and crystallisation of liabilities is dependent upon the outcome of uncertain future events or actions, not wholly within the control of the company and therefore the same has been considered as a 'Contingnet Liability" as at 30th September,2009.
- 8 The Company is primarily engaged in a single segment business of Manufacturing & Marketing of Pharmaceutical Formulations and Active Pharmaceuticals Ingridents and is managed as one entity, for its various activities and is governed by similar set of risk and returns.
- 9 There were no pending investor complaints at the beginning of the Quarter and 2 complaints were received during the Quarter, which have been attended and resolved and there was no complaint pending at the end of the Quarter.
- 10 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

Place: Mumbai.

Date: October 30,2009.

Visit us at [www.marksanspharma.com](http://www.marksanspharma.com)

**MARK SALDANHA**  
Managing Director.